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Abstract
Background: Systemic lupus erythematosus (SLE), an autoimmune disease, predominantly affects women of childbearing
age. Moreover, increased serum levels of interferon-a (IFN-a) are associated with the disease. Although, the female sex
hormone estrogen (E2) is implicated in sex bias in SLE through up-regulation of IFN-c expression, the molecular mechanisms
remain unknown. Here we report that activation of IFN (a or c)-signaling in immune cells up-regulates expression of
estrogen receptor-a (ERa; encoded by the Esr1 gene) and stimulates expression of target genes.
Methodology/Principal Findings: We found that treatment of mouse splenic cells and mouse cell lines with IFN (a or c)
increased steady-state levels of ERa mRNA and protein. The increase in the ERa mRNA levels was primarily due to the
transcriptional mechanisms and it was dependent upon the activation of signal transducer and activator of transcription-1
(STAT1) factor by IFN. Moreover, the IFN-treatment of cells also stimulated transcription of a reporter gene, expression of
which was driven by the promoter region of the murine Esr1 gene. Notably, splenic cells from pre-autoimmune lupus-prone
(NZB 6NZW)F1 female mice had relatively higher steady-state levels of mRNAs encoded by the IFN and ERa-responsive
genes as compared to the age-matched males.
Conclusions/Significance: Our observations identify a novel mutually positive regulatory feedback loop between IFNs and
ERa in immune cells in mice and support the idea that activation of this regulatory loop contributes to sex bias in SLE.
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Introduction
Systemic lupus erythematosus (SLE) is a prototype autoimmune
disease in which patients develop pathogenic autoantibodies
against nuclear antigens and the disease involves multiple organs,
including the kidneys [1,2]. The disease has a strong sex bias and
develops at a female-to-male ratio of 10:1 [3–6]. The sex bias in
SLE is thought to be influenced by sex hormones, such as estrogen
and androgen [4–6]. Additionally, it has been noted [7] that ERa
mRNA levels are significantly higher in peripheral blood
mononuclear cells (PBMCs) from SLE patients as compared to
normal controls. Moreover, the female sex hormone estrogen (E2)
is known to have immunomodulatory effects [5]. For example, in
vitro treatment of PBMCs from SLE patients with estrogen results
in polyclonal activation, secretion of antibodies to double-stranded
DNA, and defects in apoptosis of immune cells [5,6].
Sex hormones also influence the pathogenesis of murine lupus
[8–11]. For example, in (NZB 6NZW) F1 mouse model of SLE
disease, female mice develop the disease earlier and have shorter
life spans than males [8]. In contrast, castrated male (NZB 6
NZW) F1 mice have earlier onset of lupus and shorter life span
than their intact littermates [9]. In addition treatment with
estrogen exacerbates disease activity and causes early mortality
[10,11].
Estrogen functions by activating one of its two nuclear
receptors, ERa and ERb [12,13]. Both receptors are expressed
in most immune cells [14]. Several recent studies involving mouse
models of SLE disease have provided evidence for a prominent
role of ERa in the development of lupus disease [10,11,15,16].
Interestingly, the ERa deficiency in (NZB 6 NZW) F1 female
mice attenuated glomerulonephritis and increased survival of mice
[15]. Of note, the increased survival of ERa deficient female mice
was associated with reduced development of anti-chromatin and
anti-dsDNA antibodies as well as reduced serum levels of IFN-c
[15]. Moreover, E2 is known to promote IFN-c production by
invariant natural killer T cells [17], dendtritic cells [18], and
splenocytes [19]. Interestingly, the participation of IFN-c in lupus
pathogenesis has been demonstrated in mice [20] and in SLE
patients [21]. Consistent with a role for IFN-c in the development
of lupus disease, deletion of the IFN-c receptor [22] or depletion of
IFN-c in lupus-prone (NZB 6 NZW)F1 mice [23] prevents
autoantibody production and glomerulonephritis. These observa-
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signaling in the development of lupus disease in mouse models.
Studies have indicated that SLE patients with active disease have
elevated serum levels of type I IFNs (IFN-a/b) [20,24]. It has been
proposed that tissue damage, either as a result of infections or sterile
injuries could be source of apoptotic debris and, thus, autoantigen,
which in turn can induce the type I IFN production [25]. Moreover,
consistent with increased serum levels of IFN-a in SLE patients,
PBMCs from SLE patients also exhibit a gene expression profile
indicative of an active IFN-a signaling [24,25]. The role of type I IFN-
signaling has also been investigated in mouse models of SLE [20]. It is
known that mice that are deficient in the type I receptor do not develop
the disease [20]. Interestingly, a comparison of gene expression analysis
between pre-autoimmune (NZB 6NZW) F1 and MRL/lpr mice has
suggested that mononuclear cells from (NZB6NZW) F1 female mice
express higher levels of IFN-a and IFN-c-inducible genes than the
MRL/lpr mice [26]. Moreover, our work revealed that the type I
interferon receptor deficiency reduces lupus-like disease in the lupus-
prone NZB mice [27]. Although, the above studies using mouse
models of SLE and human SLE patients have also provided evidence
for a role for IFN-signaling in lupus disease, it remains unclear whether
the increased levels of IFNs contribute to sex bias in SLE.
Type I IFNs are multifunctional cytokines with potent immuno-
modulatory activities [20]. In IFN-responsive cells, binding of Type
I IFNs to cell surface receptor results in activation of the receptor-
associated Janus tyrosine kinases, Jak1 and Tyk2, which in turn
leads to tyrosine phosphorylation and activation of latent transcrip-
tion factors termed STATs [28]. The activated STATs then form
homodimers or heterodimers and translocate into the nucleus, bind
to conserved promoter sequences termed interferon stimulated
response element (ISRE), and induce the transcription of IFN-
responsive genes. The IFN-stimulated gene factor 3 (ISGF3), which
includes IRF9, and Stat1:Stat2 heterodimers binds to the ISRE
sequence and activates transcription of the target genes. Notably,
the type IFNs can also activate transcription of certain IFN-
responsive genes independent of the Jak/STAT pathway [29].
Numerous studies have suggested role for IFN [20,24,25] and
estrogen [4–6] signaling in the development of SLE. Moreover, the
female hormone estrogen is known to up-regulate the expression of
IFN-c in immune cells [15,17–19]. Therefore, we explored whether
IFNs could regulate expression of ERa. Here, we report that the
IFNs (a or c) up-regulate the expression of ERa and stimulate the
ERa-mediated transcriptional activation of genes.
Materials and Methods
Mice and Cells
All mice were handled in accordance with good animal practice
as defined by the requirement of the National Institutes of Health
and the University of Cincinnati’s animal committee, and all
experimental protocols that are used in this manuscript were
approved (approval #07-05-24-01) by the University of Cincinna-
ti’s Animal Care and Use Committee. Age-matched (,6–8 weeks
old) male and female C57BL/6J and (NZB6NZW) F1 mice were
purchased from The Jackson Laboratory. Age-matched wild type
and homozygous Stat1-null 129S6/SvEv-Stat1tm1Rds mice (age
,6–8 weeks) [30] were purchased from Taconic Farm (Hudson,
NY). All mice were housed in a germ-free Laboratory Animal and
Medical Services facility of the University of Cincinnati.
Splenocyte Isolation, Cell culture, and Hormone
Treatment
Total single cell splenocytes were prepared from male or female
mice as described previously [31]. Unless, otherwise indicated,
splenic cells from two or more age-matched male or female mice
were pooled to prepare total RNA or protein extracts. Splenic B or
T cells were purified from total splenic cells using magnetic beads
from Miltenyi Biotech (Auburn, CA) as described previously [31].
Estrogen-responsive mouse breast cancer cell line WT276 [31]
was generously provided by Dr. JoEllen Welsh, University of
Notre Dame, Notre Dame, IN. Mouse RAW264.7 macrophage
cell line was purchased from ATCC. Cells were maintained in
DMEM medium supplemented with 10% fetal bovine serum and
16 antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA).
When indicated, mouse splenic cells or mouse cell lines were
treated with either IFN-a (1,000 u/ml; Universal IFN-a, from R &
D Systems, Minneapolis, MN) or murine IFN-c (10 ng/ml) for the
indicated duration. For treatment of mouse splenocytes or cell
lines with 17-b-estradiol (E2; 1–10 nM), cells were cultured in
phenol red-free RPMI 1640 medium (Invitrogen) and the medium
was supplemented with 10% charcoal-stripped fetal bovine serum
(Invitrogen). Splenocytes (5-8610
6 cells) were used to isolate total
RNA using TRIzol (Invitrogen).
Plasmids
The ERE-luc-reporter plasmid has been described previously
[32]. The ISRE-luc-reporter plasmid was purchased from B D
Biosciences (San Jose, CA). A plasmid reporter construct in which
the murine Esr1 gene promoter-region (,5-kb) is linked to the b-
galactosidase reporter gene was generously provided by Dr.
Alessandro Weisz (Seconda Universita ` degli Studi di Napoli, Italy)
and the plasmid construct has been described [33].
Reporter Assays
For reporter assays, sub-confluent cultures of WT276 cells (in 6-
well plates) were transfected with the indicated reporter plasmids
(either ERE-luc or ISRE-luc; 1.8 mg plasmid DNA) and a second
reporter plasmid pRL-TK (0.2 mg;), as an internal control to
normalize the transfections efficiency, using the FuGENE 6
transfection reagent (Roche, Indianapolis, IN), as suggested by the
supplier. When indicated, cells were either treated with ethanol
(vehicle), the indicated concentration of E2, or IFN-a (1,000 u/ml)
for 18 h. Unless, otherwise indicated, cells were harvested between
40 and 45 h after transfections. Cells were lysed, and the firefly
and Renilla dual luciferase activities were determined using a dual
luciferase assay kit (Promega, Madison, WI) as described
previously [31]. For b-galactosidase assay, a Galacto-Light Plus
Systems kit (Applied Biosystems, Bedford, MA) was used following
the manufacturer’s instructions. For this assay, the units were
normalized for total protein content measured with the Bio-Rad
protein assay reagent.
RT-PCR and Quantitative Real-Time PCR Analysis
Splenocytes (5-8610
6 cells) or purified (93–95% pure) splenic B
or T cells (2-3610
6 cells) were used to isolate total RNA using
TRIzol (Invitrogen). Total RNA (2.0 mg) was used for or RT-PCR
reaction. We used the Superscript one-step RT-PCR system from
Invitrogen. Primers for the murine Esr1 gene that were used
(forward: 59-aattctgacaatcgacgccag- 39; backward: 59-gtgcttcaa-
cattctccctcctc-39) gave a single band of 345 base pair. Quantitative
real-time TaqMan PCR technology (Applied Bio-systems, Foster
City, CA, USA) was used to quantitate the steady-state levels
of mRNAs. The PCR cycling program consisted of denaturation
at 95uC for 10 min, 40 cycles at 95uC for 15 seconds, followed
by annealing and elongation at 60uC for 1 min. The TaqMan
assays for Serpinb2 (Assay Id# Mm00440905_m1), Rab10
(#Mm00489481_m1), Ifi202 (#Mm03048198 _m1), Mx1
(#Mm00487796_m1), Syn25A (#Mm00836412_m1), Esr1 (Assay
Sex Bias in Autoimmunity
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globulin (Assay Id#Mm00437762_ m1) were purchased from
Applied Bio-systems (Foster City, CA) and used as suggested by
the supplier.
Immunoblot Analysis
Total splenocytes, purified splenic B or T cells, WT276, or
RAW264.7 cells were collected in PBS and re-suspended in a
modified radio-immune precipitation assay (RIPA) lysis buffer
(50 mM Tris-HCl, pH 8.0, 250 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholate, 0.1% SDS), supplemented with
protease inhibitors (Roche Diagnostics, Mannheim, Germany)
and phosphatase inhibitors (Sigma) and incubated at 4uC for
30 min. Cell lysates were sonicated briefly before centrifugation at
14,000 rpm in a microcentrifuge for 10 min at 4uC. The
supernatants were collected, and the protein concentration was
measured by Bio-Rad protein assay kit. Equal amounts of protein
were processed for immunoblotting. Antibodies to detect mouse
ERa (sc-542; MC-20), c-Jun (sc-1694; H-79), p-c-Jun (sc-822; KM-
1), and b2-mcroglobulin (sc-13565) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies to detect
STAT1 (#9172), p-STAT1 (#9177), and b-actin (#4967) were
purchased from Cell Signaling Technology (Danvers, MA).
Statistical Analysis
Data are presented as the means 6 S.E. For statistical
comparisons between two groups, Student’s two-tailed t test was
used. p,0.05 was considered significant.
Results
IFN-Treatment Increases Steady-state Levels of ERa
mRNA and Protein
To explore whether IFNs could regulate the expression of ERa,
we treated total splenic cells from non lupus-prone C57BL/6
female mice with either the murine IFN-a (1,000 u/ml) or IFN-c
(10 ng/ml) and compared steady-state levels of ERa mRNA by
quantitative real-time PCR. As shown in Fig. 1A, treatment of cells
with IFN-a or IFN-c measurably increased the steady-state levels
of ERa mRNA. Interestingly, the increase was more pronounced
(,50% versus 30%) after the IFN-a than IFN-c treatment. Next,
we compared the IFN-mediated increase in ERa mRNA levels
between C57BL/6 male and age-matched female mice. As shown
in Fig. 1B, treatment of total splenic cells with IFN-a measurably
increased the steady-state levels of ERa mRNA (Fig 1B) and
protein (Fig. 1C) in both male and female mice. Notably, the
extent of IFN-a-mediated increase in ERa mRNA (Fig. 1B) and
protein (Fig. 1C) was more appreciable (,2-4-fold) in male splenic
cells than the age-matched females. Moreover, basal levels of ERa
protein were reproducibly ,2-fold higher in splenic cells from
females than the age-matched males in several experiments.
Because we recently reported that the murine splenic B cells
express relatively higher levels of ERa than T cells [31], we also
compared ERa mRNA levels between purified splenic T and B
cells. As shown in Fig. 1D, as compared to T cells, the B cells had
significantly (,4-fold) higher levels of ERa mRNA. Together,
these observations revealed that IFN-a or c treatment of C57BL/6
splenic cells increases steady-state levels of ERa mRNA and
protein.
We also tested whether IFN-treatment of splenic cells from pre-
autoimmune (age ,8-weeks) lupus-prone (NZB 6NZW) F1 mice
also increases ERa expression. As shown in Fig. 2, the IFN-a
treatment of splenic cells from both male and female mice
increased the steady-state levels of ERa mRNA as determined by
both semi-quantitative (Fig. 2A) and quantitative real-time PCR
(Fig. 2B). Consistent with these observations, IFN-a treatment of
splenic cells also increased ERa protein levels ,2-4-fold (Fig. 2C).
Interestingly, basal levels of ERa mRNA (Fig. 2A, compare lane 3
with 1) and protein (Fig. 2C, compare lane 3 with 1) were
measurably higher in (NZB6NZW) F1 female mice as compared
to the age-matched male mice. Furthermore, consistent with our
above and the previous [31] observations, the basal levels of ERa
protein were about two-fold higher in purified splenic B cells from
female mice than the age-matched male mice and IFN-a
treatment of B cells further increased the levels of ERa protein
,2-4-fold (Fig. 2D).
Binding of type I IFNs to the cell surface receptor activates
multiple signaling pathways, including the classical Jak/STAT
pathway, which lead to the transcriptional activation of the IFN-
inducible genes [28,29]. Therefore, we explored whether the IFN-
treatment of splenic B cells activates the STAT1 transcription
factor. As shown in Fig. 2E, treatment of splenic B cells from (NZB6
NZW) F1 mice with IFN-a increased the activating phosphorylation
of STAT1 and basal levels of STAT1 protein in both male and
female splenic cells. Again, the extent of IFN-a-mediated increase
in the phosphorylation of STAT1 and increase in the levels of
ERa protein were more appreciable in male B cells than the age-
matched females. Moreover, the basal levels of phospho-STAT1
and ERa protein were reproducibly higher in splenic cells from
females than the age-matched males. Together, these observa-
tions suggested that the basal levels of ERa mRNA and protein
are relatively higher in splenic cells from lupus-prone (NZB 6
NZW) F1 females than the age and strain-matched males and
IFN-a (or IFN-c) treatment of splenic cells increases the steady-
state levels of ERa mRNA and protein in both males and females.
Additionally, these observations suggested that the basal levels of
phospho-STAT1 and ERa in female B cells were relatively higher
than the age-matched males and the IFN-a treatment of B cells
increased the steady-state levels of both phospho-STAT1 and
ERa further.
To investigate the molecular mechanisms by which IFN-
signaling increases the steady-state levels of ERa mRNA and
protein in mouse splenic cells, we investigated the effect of IFN-
treatment of WT276 mouse breast cancer cell line (an ERa-
positive cell line; ref. 31) on steady-state levels of ERa mRNA and
protein. As shown in Fig. 3A, treatment of cells with either IFN-a
or IFN-c increased the ERa protein levels and the extent of the
increase was dependent on the dose of IFN-a or IFN-c. Moreover,
steady-state levels of ERa mRNA were also increased after IFN-a
or IFN-c treatment as determined by semi-quantitative RT-PCR
(Fig. 3B) and quantitative real-time PCR (Fig. 3C). Similarly,
treatment of mouse macrophage cell line RAW264.7 with IFN-a
or IFN-c also increased steady-state levels of ERa mRNA and
protein in a dose-dependent manner (data not shown). Together,
these observations revealed that IFN-a or IFN-c treatment of
mouse cell lines that express ERa also increased the steady-state
levels of ERa mRNA and protein.
Interferon-signaling Increases ERa mRNA Levels Primarily
by Transcriptional Mechanism
Regulation of steady-state levels of ERa mRNA and protein is
complex and the regulation may depend on the cell type [10–13].
Moreover, the promoter of the murine Esr1 gene is reported to be
relatively weak and does not contain a TATA box [32,33,34].
Therefore, to investigate the molecular mechanisms by which
IFN-a treatment of cells increased the expression of ERa,w e
compared levels of ERa mRNA in WT276 cells that were treated
with IFN-a alone or along with actinomycin-D, an inhibitor of
Sex Bias in Autoimmunity
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with the inhibitor alone decreased basal steady-state levels of ERa
mRNA about 60% (compare column 3 with 1). Interestingly, co-
treatment of cells with IFN-a plus the inhibitor abrogated the IFN-
a-mediated increase in the ERa mRNA levels (compare column 4
with 2). Moreover, treatment of WT276 cells with IFN-a,
cycloheximide (an inhibitor of protein synthesis) or both IFN-a
plus cycloheximide increased steady-state levels of ERa mRNA
(Fig. 4B) and protein (Fig. 4C). Together, these observations
suggested that the IFN-a treatment of WT276 cells increases ERa
mRNA levels primarily through a transcriptional mechanism and
protein synthesis is required for a rapid turnover of the ERa
mRNA in WT276 cells.
Expression of the Esr1 gene is STAT1-dependent
Transcription-dependent increase in ERa mRNA levels in IFN-
treated cells (Fig. 4A) and an increased activating phosphorylation of
STAT1 in IFN-a treated B cells, which associated with increased
expression of ERa (Fig. 2E), prompted us to determine whether the
IFN-treatment indeed activates the transcriptional of the Esr1 gene.
As shown in Fig. 5A (Top panel), consistent with the presence of three
potential interferon-sensitive response elements (ISREs) consensus
sequence (TTCCCGGAA) in the 59-regulatory region of the Esr1
gene, treatment of WT276 cells with IFN-a stimulated the activity of
a reporter gene, the transcription of which was driven by the 59-
reglatory regionofthe murine Esr1gene [32]. Interestingly, consistent
with our earlier observations (Fig. 1A) the stimulation of the reporter
activity was relatively more in the IFN-a treated cells than IFN-c.T o
further investigate how IFN-signaling activates the transcription of
the Esr1 gene, we compared basal steady-sate levels of ERa mRNA
and protein between wild type and STAT1-null male and female
splenocytes. As shown in Fig. 5, steady-state levels of ERa mRNA
(Fig.5B) and protein (Fig. 5C)were significantlylowerin STAT1-null
male and females as compared to the wild-type age-matched mice.
Consistent with a role for STAT1 in IFN-mediated signaling in
transcriptional activation of the Esr1 gene, we noted that treatment of
C57BL/6 splenocytes with fludarabine, an inhibitor of STAT1
phosphorylation [36], which resulted in inhibition of STAT1
phosphorylation (Fig. 5D), was associated with significantly reduced
levels of ERa protein (Fig. 5D) and mRNA (Fig. 5E). Moreover,
treatment of cells with JNK inhibitor II (SP600125, 60 nM in
DMSO) did not result in any measurable decreases in the ERa
protein levels (data not shown). Thus, ruling out IFN-mediate
regulation of Esr1expression through the JNK/AP-1 pathway.
Figure 1. IFN-treatment increases steady-state levels of ERa mRNA and protein in C57BL/6 splenic cells. (A) Total RNA was isolated from
control (column 1), IFN-a (column 2), or IFN-c (column 3) treated total splenic cells that were prepared from female (age ,8 weeks) C57BL/6 mice. The
RNA was analyzed for steady-sate levels of Esr1 mRNA by quantitative real-time PCR. The ratio of the Esr1 mRNA to b2-microglobulin mRNA was
calculated in units (one unit being the ratio of Esr1 mRNA to b2-microglobulin mRNA). Results are mean values of triplicate experiments and error bars
representstandarddeviation(
*p,0.05).(B)TotalRNAwas isolatedfromcontrol(column1and3)orIFN-a(column2and4)treatedspleniccellsthat were
prepared from either male (age ,8 weeks) or age-matched female C57BL/6 mice. The RNA was analyzed by quantitative real-time PCR for the steady-
sate levels of Esr1 mRNA as described in (A). Results are mean values of triplicate experiments and error bars represent standard deviation (
*p,0.05;
**p,0.005). (C) Total protein extracts were prepared from control (lanes 1 and 3) or IFN-a (lanes 2 and 4) treated splenic cells that were isolated from
either male (age ,8 weeks) or age-matched female C57BL/6 mice. The total cell extracts were analyzed by immunoblotting using antibodies specific to
theindicatedproteins. Fold change in ERa protein levelsis indicatedbelow theFigure.(D)Total RNAwas isolatedfrom purifiedsplenicT cells (column 1)
or B cells (column 2) isolated from female (age ,8 weeks) C57BL/6 mice. The RNA was analyzed by quantitative real-time PCR for steady-sate levels of
Esr1 mRNA. Results are mean values of triplicate experiments and error bars represent the standard deviation (
**p,0.005).
doi:10.1371/journal.pone.0010868.g001
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higher in (NZB 6NZW) F1 females than the age-matched males
(Fig. 2E) and STAT1-null mice express relatively low levels of ERa
(Fig. 5C) prompted us to compare the specific DNA-binding
activities of STAT1 between males and female B cells. This
approach revealed that the specific DNA-binding activity of
STAT1 in nuclear extracts from C57BL/6 female B cells was
measurably higher than the age-matched males in gel-mobility
shift assays (data not shown). Moreover, IFN-treatment of cells
increased the DNA-binding relatively in extracts from both female
and male mice; however, the increase in the DNA-binding was
higher in extracts from females than males. Together, these
observations demonstrated that IFN-signaling up-regulates the
expression of the murine Esr1 gene in gender-dependent manner
through the activation of STAT1.
The IFN and E2-signaling Cooperate to Activate
Transcription
Up-regulation of ERa expression by IFN-signaling in the
murine cells in the above experiments prompted us to determine
whether the IFN and E2-signaling cooperate with each other to
Figure 2. IFN-treatment increases steady-state levels of ERa mRNA and protein in splenic cells from lupus-prone (NZB 6NZW) F1
mice. (A) Total RNA isolated from control (lanes 1 and 3) or IFN-a (lanes 2 and 4) treated total splenic cells that were isolated from either male (age
,8 weeks) or age-matched female (NZB 6NZW) F1 mice. The total RNA was analyzed for steady-state levels of Esr1 mRNA by semi-quantitative RT-
PCR. Fold change in Esr1 mRNA levels is indicated below the Figure. (B) Total RNA isolated from control (columns 1 and 3) or IFN-a (columns 2 and 4)
treated total splenic cells that were isolated from either male (age ,8 weeks) or age-matched female (NZB 6NZW) F1 mice. The total RNA was
analyzed for the steady-state levels of Esr1 mRNA by quantitative real-time PCR. Results are mean values of triplicate experiments and error bars
represent standard deviation (
*p,0.05; NS, not significant). (C) Total protein extracts were prepared from control (lanes 1 and 3) or IFN-a (lanes 2 and
4) treated splenic cells that were isolated from either male (age ,8 weeks) or age-matched female (NZB6NZW)F1 mice. The total cell extracts were
analyzed by immunoblotting using antibodies specific to the indicated proteins. Fold change in ERa protein levels is indicated below the Figure. (D
and E) Total protein extracts were prepared from control (lanes 1 and 3) or IFN-a (lanes 2 and 4) treated purified splenic B cells that were isolated from
either male (age ,8 weeks) or age-matched female (NZB6NZW) F1 mice. The total cell extracts were analyzed by immunoblotting using antibodies
specific to the indicated proteins. Fold change in ERa protein levels is indicated below the Figures.
doi:10.1371/journal.pone.0010868.g002
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treatment of WT276 cells with E2 stimulated the activity of an E2-
responsive reporter about 3-fold (compare column 2 with 1).
However, treatment of cells with IFN-a (in the absence of E2) did
not result in stimulation of the activity of the reporter (compare
column 3 with 1). Interestingly, treatment of cells with both E2 and
Figure 3. IFN-treatment increases steady-state levels of ERa mRNA and protein in mouse breast cancer cell line WT276. (A) Total
protein extracts were prepared from control (lane 1), increasing concentrations (1,000 or 2000 u/ml) of IFN-a (lanes 2 and 3, respectively) or IFN-c (5
or 10 ng/ml; lanes 4 and 5, respectively) treated WT276 cells. As a negative control, we also included extracts from AKR-2B cells. The extracts were
analyzed by immunoblotting using the antibodies specific to the indicated proteins. Fold change in ERa protein levels is indicated below the Figure.
(B) Total RNA was isolated from control (lane 1), increasing concentrations of IFN-a (lanes 2 and 3) or IFN-c (lanes 4 and 5) treated WT276 cells. As a
positive control, we also included RNA from splenic cells. The total RNA was analyzed for steady-state levels of Esr1 mRNA by semi-quantitative RT-
PCR. Fold change in ERa mRNA levels is indicated below the Figure. (C) Total RNA was isolated from control (column 1), increasing concentrations of
IFN-a (columns 2 and 3) or IFN-c (columns 4 and 5) treated WT276 cells. The total RNA was analyzed for steady-state levels of Esr1 mRNA by
quantitative real-time PCR. Results are mean values of triplicate experiments and error bars represent standard deviation (
*p,0.05).
doi:10.1371/journal.pone.0010868.g003
Figure 4. Interferon-signaling increases ERa mRNA levels primarily by Transcriptional mechanism. (A) Total RNA was isolated from
control (column 1), IFN-a (column 2), actinomycin D (column 3), or both IFN-a and actinomycin D (column 4) treated WT276 cells. The RNA was
analyzed by quantitative real-time PCR for steady-sate levels of Esr1 mRNA. Results are mean values of triplicate experiments and error bars represent
standard deviation (
*p,0.05;
***p,0.0005). (B) Total RNA was isolated from control (column 1), IFN-a (column 2), cycloheximide (column 3), or both
IFN-a and cycloheximide (column 4) treated WT276 cells. The RNA was analyzed by quantitative real-time PCR for steady-sate levels of Esr1 mRNA.
Results are mean values of triplicate experiments and error bars represent standard deviation (
*p,0.05;
**p,0.005). (C) Total cell extracts were
prepared from control (lane 1), IFN-a (lane 2), cycloheximide (lane 3), or both IFN-a and cycloheximide (lane 4) treated WT276 cells. The cell extracts
were analyzed by immunoblotting using antibodies specific to the indicated proteins. Fold change in ERa protein levels is indicated below the Figure.
doi:10.1371/journal.pone.0010868.g004
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of reporter (compare column 4 with 2). Because treatment of
WT276 cells with E2 did not result in measurable increases (or
decreases) in the ERa mRNA levels (data not shown), the above
observations indicated that the IFN-induced levels of ERa increase
the E2-mediated transcription of the ERa target genes.
Because E2 treatment of ER-positive cells is known to result in
production of IFN-c in a variety of cells [17–19], which up-
regulates expression of IRF9 (a component of the ISGF3
transcription factor; ref. 29), we also tested whether treatment
of cells with E2 alone or both E2 and IFN-a has any effect on
expression of an IFN-responsive reporter gene. As shown in
Fig. 6B, treatment of WT276 cells with E2 alone resulted in ,3-
fold stimulation of the activity of the ISRE-luc-reporter, an IFN-
responsive reporter. Furthermore, treatment of cells with IFN-a
alone stimulated the activity of the reporter ,5-fold. Interest-
ingly, treatment of cells with both IFN-a and E2 stimulated the
activity of reporter ,14-fold. Together, our observations
indicated that both E2 and IFN-a signaling cooperate with each
other to activate the transcription of certain ERa and IFN-
responsive genes.
Sex Bias in the Expression of IFN and E2-responsive
Genes
Increased steady-state levels of ERa mRNA (Fig. 2A) protein
(Fig. 2B and C) in splenic cells from (NZB6NZW) F1 female mice
as compared to age-matched male mice and cooperation between
theIFNand E2-signalingincellstoactivatetranscriptionofreporter
genes (Fig. 6) prompted us to investigate whether the expression of
E2 or IFN-responsive genes is differentially regulated between male
and female (NZB 6 NZW) F1 lupus-prone mice. As shown in
Fig.7A,we noted that steady-state levelsof mRNAs encodedby two
E2-responsive genes were relatively higher in female (NZB6NZW)
F1 mice than the age-matched males (Fig. 7A). Similarly, steady-
state levels of mRNA encoded by three IFN-responsive genes were
relatively higher in female mice than the age-matched male mice
(Fig. 7B). Together, these observations demonstrated a sex bias in
the expression of both E2 and IFN-responsive genes.
Discussion
The development of SLE is known to have a strong sex bias
[3–6]. Moreover, peak SLE disease incidence in women occurs
Figure 5. Expression of the Esr1 gene is dependent on activation of STAT1. (A) Top panel: Schematic presentation of the 59-regulatory
region of the murine Esr1 gene (the NCBI accession # for the sequence: NT_039490.7) and potential cis-elements that are predicted to render the
gene responsive to the IFN treatment. The regulatory sequence for the gene is derived from the C57BL/6J strain of mice. The regulatory region
includes three potential ISREs for binding of activated STAT1 (ISGF3) transcription factor. Bottom panel: Sub-confluent cultures of WT276 cells in a 6-
well plate were transfected with ERa promoter-b-galactosidase plasmid (2 mg) along with pRL-TK (0.2 mg) plasmid using the FuGene 6 transfection
agent. 24 h after transfections, cells were either left untreated treated (column1), treated with IFN-a (column 2), or IFN-c (column 3). 40–45 h after
transfections, cells were lysed and the lysates were processed for estimation of protein followed by b-galactosidase activity assays. (B) Total RNA was
isolated from wilt-type (columns 1 and 3) or STAT1-null (columns 2 and 4) total splenic cells that were prepared from male or age-matched female
(age ,8 weeks) mice. The RNA was analyzed by quantitative real-time PCR for steady-sate levels of Esr1 mRNA. (C) Total cell extracts were prepared
from wilt-type (lanes 1 and 3) or STAT1-null (lanes 2 and 4) total splenic cells that were prepared from male or age-matched female (age ,8 weeks)
mice. The RNA was analyzed by quantitative real-time PCR for steady-sate levels of Esr1 mRNA. Fold change in ERa protein levels is indicated below
the Figure. (D) Total cell isolated from C57BL/6 were either left untreated (lane 1) or treated with fludarabine (lane 2) for 24 h. Total cell extracts were
prepared and analyzed by immunoblotting using antibodies specific to the indicated proteins. Fold change in ERa protein levels is indicated below
the Figure. (E) Total cell isolated from C57BL/6 were either left untreated (lane 1) or treated with fludarabine (lane 2) for 24 h. Total RNA was prepared
and steady-state levels of Esr1 mRNA were analyzed by quantitative real-time PCR. Results are mean values of triplicate experiments and error bars
represent standard deviation (
**p,0.005).
doi:10.1371/journal.pone.0010868.g005
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PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10868Figure 6. The IFN and E2-signaling cooperate to activate transcription of genes. (A) Sub-confluent cultures of WT276 cells in a 6-well plate
were transfected with ERE-luc-reporter plasmid (2 mg) along with pRL-TK (0.2 mg) plasmid using FuGENE 6 transfection reagent. 24 h after
transfections, cells were either left untreated (column 1), treated with E2 (column 2), IFN-a (column 3) or E2 and IFN-a (column 4). 40–45 h after
transfections, cells were processed for dual luciferase activity. Result are mean values of triplicate experiments and error bars represent standard
deviation (p value is 0.006). (B) Sub-confluent cultures of WT276 cells in a 6-well plate were transfected with ISRE-luc-reporter plasmid (2 mg) along
with pRL-TK (0.2 mg) plasmid using FuGENE 6 transfection reagent. 24 h after transfections, cells were either left untreated (column 1), treated with E2
(column 2), IFN-a (column 3) or E2 and IFN-a (column 4). 40–45 h after transfections, cells were processed for dual luciferase activity.
doi:10.1371/journal.pone.0010868.g006
Figure 7. Sex bias in the expression of IFN and E2-responsive genes. (A and B) Total RNA isolated from pre-autoimmune (age ,8 weeks) male
or age-matchedfemale(NZB6NZW)F1 micewasanalyzedforsteady-statelevelsoftheindicatedknownestrogen-responsive(A)andIFN-responsive(B)
genes by quantitative real-time PCR. Results are mean values of triplicate experiments and error bars represent standard deviation (
*p,0.05;
**p,0.005).
doi:10.1371/journal.pone.0010868.g007
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Additionally, risk of SLE development is associated with the use of
combined oral contraceptives [38]. Studies have revealed that
PBMCs from SLE patients overexpress IFN-a-inducible genes as
compared with healthy individuals [7] and high serum IFN-a level
is a heritable risk factor for SLE development [37]. Notably,
activation of TLR7-induced signaling is associated with higher
IFN-a production in females [39] and the peak time frame for
lupus onset in women coincides with an increase in IFN-a activity
[37]. In light of the above observations, our observations that: (i)
activation of IFN-signaling up-regulates the expression of ERa
(Figs. 1, 2 and 3); and (ii) E2 and IFN-signaling cooperate to
activate transcription of certain target genes (Figs. 6 and 7) provide
support for the idea that the female sex hormone estrogen and
increased levels of IFN-a contribute to sex bias in SLE through the
activation of a mutually positive feedback loop.
A recent study [40] has revealed that estrogen treatment of
splenocytes enhances STAT1 DNA-binding activity without
increasing the levels of phosphorylated and total STAT1.
Furthermore, the study also noted that estrogen induces serine
protease-mediated proteolysis of STAT1, which may alter and
enhance the activity of the transcription factor. In contrast to this
report, we noted that steady-state levels of phospho-STAT1 and
total STAT1 were consistently higher in splenocytes from female
mice than the age-matched males. Moreover, we did not detect
any additional forms of the STAT1 in extracts from female mice as
compared to males (data not shown). Therefore, further work will
be needed to resolve this apparent discrepancy.
A study [10] revealed that treatment of BALB/c mice with ER-
subtype-selective agonists that results in activation of ERa, but not
ERb, plays a major role in estrogen-induced thymic atrophy and
thymic T cell and splenic B cell phenotype alterations. Moreover,
the study also revealed that ERa, but not ERb, mediates the
estrogen-induced up-regulation of IFN-c. Similarly, a recent study
has demonstrated a role for ERa in E2-induced development of
the lupus phenotype in mice [16]. Consistent with these studies,
generation of ERa knockout (NZB 6 NZW)F1 mice and their
characterization revealed that E2 through ERa promotes lupus
disease, in part, by inducing the IFN-c production [15]. Moreover,
estrogen is known to enhance IFN-c production by CD11c
+ cells
[18]. Together, these observations raise the possibility that
estrogen signaling through ERa in certain strains of female mice
up-regulates expression of IFN-inducible genes, in part, by
increasing the production of IFN-c (Fig. 8).
The murine Esr1 gene is transcribed from a complex transcrip-
tionunit with multiple potential promoters and upstream regulatory
sequences [32,34]. Consistent with this observation, multiple
transcription start sites have been identified in the regulatory region
of the gene. Moreover, the promoter of the Esr1 gene is reported to
be relatively weak [33]. Therefore, our observations that treatment
of cells with IFN-a or IFN-c resulted in a modest stimulation of the
activityofthe reporter,theexpression ofwhichwasdrivenbythe59-
regulatory region (,5-kb) of the Esr1 gene (Fig. 5A), are consistent
with the above reports.
A study [26] has noted differences in estrogen receptors levels
between BALB/c mice, which do not get autoimmune disease and
two strains that do (MRL/MP-lpr/lpr and NZB/W mice). Therefore,
our observations that basal as well as IFN-induced levels of ERa were
relatively higher in non lupus-prone (C57BL/6) as well as lupus-
prone (NZB 6NZW) F1 female mice as compared to the age and
strain-matched males will require further work to determine whether
other factors, such as promoter polymorphisms in the Esr1 gene, also
contribute to differential expression of ERa in certain strains of mice.
Notably, a study has provided evidence that the XX sex
chromosome complement, as compared with XY, confers greater
susceptibility to certain autoimmune diseases, such as experimental
autoimmune encephalomyelitis (EAE) and pristane-induced lupus
[41].However,itremains unclearwhetherthe XXsexchromosome
complement also contributes to sex bias in mouse models of lupus
disease,such as(NZB6NZW) F1, whichspontaneously develop the
disease. Therefore, further work will be needed to investigate the
role of XX sex chromosomes in these mouse models of the disease.
In summary, our observations provide support for our model
(Fig. 8). The model predicts that increased levels of IFNs (IFN-a or
IFN-c) in serum of SLE patients and certain lupus-prone strains of
female mice, by up-regulating the expression of ERa, potentiate the
expression of certain E2 and IFN-responsive genes. Notably,
increased expression of the IFN-inducible genes is associated with
the active disease in SLE patients [20,24] and certain lupus-prone
strains of mice [26]. Importantly, increased expression of these IFN-
inducible genes is associated with increased survival of autoreactive
immune cells and autoimmunity [20,24,31]. Therefore, our
observations concerning a mutually positive feedback loop between
IFNs and ERa in mice provide a potential molecular basis for the
sex bias in SLE. Further work will be needed to determine whether
increasedlevels oftype I IFNinSLEpatientsareassociated with up-
regulation of ERa expression and active SLE.
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Figure 8. Cooperation between the IFN and E2-signaling in sex
bias in SLE in mice. Increased levels of type I IFNs up-regulate
expression of ERa. Activation of ERa by the female sexhormoneestrogen
leads to up-regulation of IFN-c and IFN-c-inducible IRF9. Increased levels
of the IRF9 potentiate ISGF3-mediated transcription of IFN-inducible
genes, which mediate the immunomodulatory functions of the IFNs.
doi:10.1371/journal.pone.0010868.g008
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